Time To Buy Bristol Myers (NYSE:BMY)? SunTrust Robinson Upgrades Shares Today

January 19, 2018 - By Vivian Currie

  Time To Buy Bristol Myers (NYSE:BMY)? SunTrust Robinson Upgrades Shares Today

Investors sentiment increased to 1.03 in Q3 2017. Its up 0.08, from 0.95 in 2017Q2. It is positive, as 62 investors sold Bristol-Myers Squibb Company shares while 519 reduced holdings. 137 funds opened positions while 460 raised stakes. 1.11 billion shares or 0.68% more from 1.10 billion shares in 2017Q2 were reported.

Agf Invests America Inc reported 0.66% stake. Lenox Wealth Advsr holds 0% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY) for 5 shares. Stifel Corporation has invested 0.2% in Bristol-Myers Squibb Company (NYSE:BMY). Acropolis Invest Mngmt Limited Liability Co has invested 0.06% in Bristol-Myers Squibb Company (NYSE:BMY). Somerville Kurt F, Massachusetts-based fund reported 20,850 shares. 549,557 are owned by Commerzbank Aktiengesellschaft Fi. The Missouri-based Argent Capital has invested 0.63% in Bristol-Myers Squibb Company (NYSE:BMY). First Eagle Invest Limited Com holds 49,229 shares or 0.01% of its portfolio. Schroder Inv Gru reported 0.06% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). First Natl Bank reported 26,477 shares. The Pennsylvania-based Fulton National Bank Na has invested 0.1% in Bristol-Myers Squibb Company (NYSE:BMY). Perkins Coie Trust Company accumulated 0.1% or 3,084 shares. Zacks Mngmt owns 0.74% invested in Bristol-Myers Squibb Company (NYSE:BMY) for 494,129 shares. Natl Bank Of New York Mellon Corporation reported 18.86 million shares. Atlas Browninc stated it has 0.14% in Bristol-Myers Squibb Company (NYSE:BMY).

Since September 6, 2017, it had 1 insider buy, and 2 selling transactions for $646,385 activity. Caldarella Joseph C also sold $560,400 worth of Bristol-Myers Squibb Company (NYSE:BMY) on Wednesday, September 6. Samuels Theodore R. II also bought $249,187 worth of Bristol-Myers Squibb Company (NYSE:BMY) on Friday, December 15.

Bristol Myers (NYSE:BMY) Stock Upgrade

In an analyst note released on Monday morning, SunTrust Robinson raised their rating for shares of Bristol Myers (NYSE:BMY) to a Buy.

Investors sentiment increased to 1.03 in Q3 2017. Its up 0.08, from 0.95 in 2017Q2. It is positive, as 62 investors sold Bristol-Myers Squibb Company shares while 519 reduced holdings. 137 funds opened positions while 460 raised stakes. 1.11 billion shares or 0.68% more from 1.10 billion shares in 2017Q2 were reported.

Agf Invests America Inc reported 0.66% stake. Lenox Wealth Advsr holds 0% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY) for 5 shares. Stifel Corporation has invested 0.2% in Bristol-Myers Squibb Company (NYSE:BMY). Acropolis Invest Mngmt Limited Liability Co has invested 0.06% in Bristol-Myers Squibb Company (NYSE:BMY). Somerville Kurt F, Massachusetts-based fund reported 20,850 shares. 549,557 are owned by Commerzbank Aktiengesellschaft Fi. The Missouri-based Argent Capital has invested 0.63% in Bristol-Myers Squibb Company (NYSE:BMY). First Eagle Invest Limited Com holds 49,229 shares or 0.01% of its portfolio. Schroder Inv Gru reported 0.06% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). First Natl Bank reported 26,477 shares. The Pennsylvania-based Fulton National Bank Na has invested 0.1% in Bristol-Myers Squibb Company (NYSE:BMY). Perkins Coie Trust Company accumulated 0.1% or 3,084 shares. Zacks Mngmt owns 0.74% invested in Bristol-Myers Squibb Company (NYSE:BMY) for 494,129 shares. Natl Bank Of New York Mellon Corporation reported 18.86 million shares. Atlas Browninc stated it has 0.14% in Bristol-Myers Squibb Company (NYSE:BMY).

Since September 6, 2017, it had 1 insider buy, and 2 selling transactions for $646,385 activity. Caldarella Joseph C also sold $560,400 worth of Bristol-Myers Squibb Company (NYSE:BMY) on Wednesday, September 6. Samuels Theodore R. II also bought $249,187 worth of Bristol-Myers Squibb Company (NYSE:BMY) on Friday, December 15.

Bristol-Myers Squibb Company (NYSE:BMY) Ratings Coverage

Among 19 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 6 have Buy rating, 3 Sell and 10 Hold. Therefore 32% are positive. Bristol-Myers Squibb Company has $80 highest and $45 lowest target. $62.53’s average target is 0.84% above currents $62.01 stock price. Bristol-Myers Squibb Company had 69 analyst reports since July 28, 2015 according to SRatingsIntel. BMO Capital Markets maintained the stock with “Underperform” rating in Friday, July 28 report. Leerink Swann maintained the stock with “Outperform” rating in Monday, October 23 report. The rating was maintained by Piper Jaffray with “Hold” on Thursday, July 27. The rating was upgraded by SunTrust on Monday, October 30 to “Buy”. The firm earned “Equal-Weight” rating on Friday, October 13 by Barclays Capital. The stock of Bristol-Myers Squibb Company (NYSE:BMY) earned “Hold” rating by Jefferies on Tuesday, March 15. The stock has “Hold” rating by Jefferies on Tuesday, June 14. The rating was maintained by Jefferies on Monday, July 17 with “Buy”. The company was maintained on Monday, October 16 by SunTrust. The firm has “Hold” rating given on Thursday, October 26 by Piper Jaffray.

The stock increased 0.29% or $0.18 during the last trading session, reaching $62.01. About 3.89 million shares traded. Bristol-Myers Squibb Company (NYSE:BMY) has declined 23.19% since January 19, 2017 and is downtrending. It has underperformed by 39.89% the S&P500.

Analysts await Bristol-Myers Squibb Company (NYSE:BMY) to report earnings on January, 25. They expect $0.67 earnings per share, up 6.35 % or $0.04 from last year’s $0.63 per share. BMY’s profit will be $1.10B for 23.14 P/E if the $0.67 EPS becomes a reality. After $0.75 actual earnings per share reported by Bristol-Myers Squibb Company for the previous quarter, Wall Street now forecasts -10.67 % negative EPS growth.

Bristol-Myers Squibb Company discovers, develops, licenses, makes, markets, and distributes biopharmaceutical products worldwide. The company has market cap of $101.49 billion. The firm offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection . It has a 24.33 P/E ratio. The Company’s products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma.

More important recent Bristol-Myers Squibb Company (NYSE:BMY) news were published by: Streetinsider.com which released: “Bristol-Myers Squibb (BMY) PT Jumps to $60 At Deutsche Bank” on January 19, 2018, also Nasdaq.com published article titled: “Ex-Dividend Reminder: Bristol-Myers Squibb, Brixmor Property Group and Kite …”, Livetradingnews.com published: “Bristol-Myers Squibb Co (NYSE:BMY) Bullish Divergence” on January 09, 2018. More interesting news about Bristol-Myers Squibb Company (NYSE:BMY) was released by: Reuters.com and their article: “Bristol-Myers sees $3 billion tax hit in fourth quarter 2017” with publication date: January 05, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: